SIRFLOX study presented at ASCO 2015 Annual Meeting
The SIRFLOX randomized controlled study found that adding liver-directed SIR-Spheres Y-90 resin microspheres to first-line chemotherapy improved liver tumour control and reduced progression risk. The regimen provided a 7.9-month treatment benefit, translating to a 31% reduction in tumour progression risk.